186 related articles for article (PubMed ID: 19457816)
1. High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function.
Bridges MD; St Amant BS; McNeil RB; Cernigliaro JG; Dwyer JP; Fitzpatrick PM
AJR Am J Roentgenol; 2009 Jun; 192(6):1538-43. PubMed ID: 19457816
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study.
Janus N; Launay-Vacher V; Karie S; Clement O; Ledneva E; Frances C; Choukroun G; Deray G
Eur J Radiol; 2010 Feb; 73(2):357-9. PubMed ID: 19128909
[TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis: center case review.
Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
6. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
Rydahl C; Thomsen HS; Marckmann P
Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
[TBL] [Abstract][Full Text] [Related]
8. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.
Broome DR; Girguis MS; Baron PW; Cottrell AC; Kjellin I; Kirk GA
AJR Am J Roentgenol; 2007 Feb; 188(2):586-92. PubMed ID: 17242272
[TBL] [Abstract][Full Text] [Related]
9. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis in liver disease: a systematic review.
Mazhar SM; Shiehmorteza M; Kohl CA; Middleton MS; Sirlin CB
J Magn Reson Imaging; 2009 Dec; 30(6):1313-22. PubMed ID: 19937937
[TBL] [Abstract][Full Text] [Related]
11. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
[TBL] [Abstract][Full Text] [Related]
12. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
Tsushima Y; Kanal E; Thomsen HS
Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
[TBL] [Abstract][Full Text] [Related]
13. Incidence of nephrogenic systemic fibrosis at two large medical centers.
Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
Bryant BJ; Im K; Broome DR
Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
[TBL] [Abstract][Full Text] [Related]
15. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
[TBL] [Abstract][Full Text] [Related]
16. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
18. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients.
Abujudeh HH; Rolls H; Kaewlai R; Agarwal S; Gebreananya ZA; Saini S; Schaefer PW; Kay J
J Magn Reson Imaging; 2009 Dec; 30(6):1335-40. PubMed ID: 19937927
[TBL] [Abstract][Full Text] [Related]
19. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
Wertman R; Altun E; Martin DR; Mitchell DG; Leyendecker JR; O'Malley RB; Parsons DJ; Fuller ER; Semelka RC
Radiology; 2008 Sep; 248(3):799-806. PubMed ID: 18632533
[TBL] [Abstract][Full Text] [Related]
20. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
